论文标题
IGLU 2.0:一种用于智能医疗保健的新的非侵入性,准确的血清血糖
iGLU 2.0: A new non-invasive, accurate serum glucometer for smart healthcare
论文作者
论文摘要
为了获得最佳作者知识,本文介绍了有史以来第一个不创的非侵入性血糖仪,该血糖仪考虑了血清葡萄糖的高精度。在血糖测量的情况下,血清葡萄糖值一直被认为是奶奶模式期间精确的血糖值。与毛细血管葡萄糖相比,可以在实验室和更稳定的葡萄糖水平中测量血清葡萄糖。但是,这种侵入性方法对于频繁测量并不方便。有时,常规的侵入性血糖测量可能是导致创伤的原因和与血液相关的感染的原因。为了克服这个问题,在当前的论文中,我们提出了一种新型的医学Inforet(IOMT),启用了葡萄糖,以实现非侵入性精确的血清葡萄糖测量。在这项工作中,已将近红外(NIR)光谱技术用于葡萄糖测量。称为IGLU 2.0的新型设备基于光学检测和精确的机器学习(ML)回归模型。已经提出了最佳的多项式回归和深度神经网络模型,以分析精确的测量。血清的葡萄糖值通过开放的物联网平台保存在云中,用于远程内分泌学家。为了验证IGLU 2.0,从毛细血管葡萄糖的预测血糖值中分别获得平均绝对相对差(MARD)和平均误差(AVGE)分别获得6.07%和6.09%。对于血清葡萄糖,MARD和AVGE分别分别为4.86%和4.88%。这些结果表明,与毛细血管葡萄糖相比,提出的非侵入性葡萄糖测量装置对于血清葡萄糖更为精确。
To best of the authors knowledge, this article presents the first-ever non-invasive glucometer that takes into account serum glucose for high accuracy. In case of blood glucose measurement, serum glucose value has always been considered precise blood glucose value during prandial modes. Serum glucose can be measured in laboratory and more stable glucose level compare to capillary glucose. However, this invasive approach is not convenient for frequent measurement. Sometimes, Conventional invasive blood glucose measurement may be responsible for cause of trauma and chance of blood related infections. To overcome this issue, in the current paper, we propose a novel Internet-of-Medical (IoMT) enabled glucometer for non-invasive precise serum glucose measurement. In this work, a near-infrared (NIR) spectroscopic technique has been used for glucose measurement. The novel device called iGLU 2.0 is based on optical detection and precise machine learning (ML) regression models. The optimal multiple polynomial regression and deep neural network models have been presented to analyze the precise measurement. The glucose values of serum are saved on cloud through open IoT platform for endocrinologist at remote location. To validate iGLU 2.0, Mean Absolute Relative Difference (mARD) and Average Error (AvgE) are obtained 6.07% and 6.09%, respectively from predicted blood glucose values for capillary glucose. For serum glucose, mARD and AvgE are found 4.86% and 4.88%, respectively. These results represent that the proposed non-invasive glucose measurement device is more precise for serum glucose compared to capillary glucose.